1
|
Dempke WC, Suto T and Reck M: Targeted
therapies for non-small cell lung cancer. Lung Cancer. 67:257–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Centers for Disease Control and Prevention
(CDC). Lung Cancer Fact Sheet. CDC; Atlanta, GA, USA: pp. 156–157.
2009
|
3
|
Rübsamen K, Breithaupt H and Habermann E:
Biochemistry and pharmacology of the crotoxin complex. I
Subfractionation and recombination of the crotoxin complex. Naunyn
Schmiedebergs Arch Pharmakol. 270:274–288. 1971.PubMed/NCBI
|
4
|
Délot E and Bon C: Model for the
interaction of crotoxin, a phospholipase A2 neurotoxin, with
presynaptic membranes. Biochemistry. 32:10708–10713.
1993.PubMed/NCBI
|
5
|
Faure G, Harvey AL, Thomson E, Saliou B,
Radvanyi F and Bon C: Comparison of crotoxin isoforms reveals that
stability of the complex plays a major role in its pharmacological
action. Eur J Biochem. 214:491–496. 1993. View Article : Google Scholar : PubMed/NCBI
|
6
|
Aird SD, Kaiser II, Lewis RV and Kruggel
WG: A complete amino acid sequence for the basic subunit of
crotoxin. Arch Biochem Biophys. 249:296–300. 1986. View Article : Google Scholar : PubMed/NCBI
|
7
|
Corin RE, Viskatis LJ, Vidal JC and
Etcheverry MA: Cytotoxicity of crotoxin on murine erythroleukemia
cells in vitro. Invest New Drugs. 11:11–15. 1993. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rudd CJ, Viskatis LJ, Vidal JC and
Etcheverry MA: In vitro comparison of cytotoxic effects of crotoxin
against three human tumors and a normal human epidermal
keratinocyte cell line. Invest New Drugs. 12:183–184. 1994.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Newman RA, Vidal JC, Viskatis LJ, Johnson
J and Etcheverry MA: VRCTC-310 - a novel compound of purified
animal toxins separates antitumor efficacy from neurotoxicity.
Invest New Drugs. 11:151–159. 1993. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yan CH, Yang YP, Qin ZH, Gu ZL, Reid P and
Liang ZQ: Autophagy is involved in cytotoxic effects of crotoxin in
human breast cancer cell line MCF-7 cells. Acta Pharmacol Sin.
28:540–548. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang M, Zhang X, Bai CX, Chen J and Wei
MQ: Inhibition of epidermal growth factor receptor expression by
RNA interference in A549 cells. Acta Pharmacol Sin. 25:61–67.
2004.PubMed/NCBI
|
12
|
Wang JH, Xie Y, Wu JC, et al: Crotoxin
enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1
human lung squamous carcinoma cells. Oncol Rep. 27:1341–1347.
2012.PubMed/NCBI
|
13
|
Wang Q, Tan YX, Ren YB, et al: Zinc finger
protein ZBTB20 expression is increased in hepatocellular carcinoma
and associated with poor prognosis. BMC Cancer. 11:2712011.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
15
|
Donato NJ, Martin CA, Perez M, Newman RA,
Vidal JC and Etcheverry M: Regulation of epidermal growth factor
receptor activity by crotoxin, a snake venom phospholipase A2
toxin. A novel growth inhibitory mechanism. Biochem Pharmacol.
51:1535–1543. 1996. View Article : Google Scholar : PubMed/NCBI
|
16
|
Condrea E: Membrane-active polypeptides
from snake venom: cardiotoxins and haemocytotoxins. Experientia.
30:121–129. 1974. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yan CH, Liang ZQ, Gu ZL, Yang YP, Reid P
and Qin ZH: Contributions of autophagic and apoptotic mechanisms to
CrTX-induced death of K562 cells. Toxicon. 47:521–530. 2006.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Cura JE, Blanzaco DP, Brisson C, et al:
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2),
NSC-624244) in patients with advanced cancer. Clin Cancer Res.
8:1033–1041. 2002.PubMed/NCBI
|
19
|
Stinchcombe TE and Bogart JA: Novel
approaches of chemoradiotherapy in unresectable stage IIIA and
stage IIIB non-small cell lung cancer. Oncologist. 17:682–693.
2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Li Y and Song L: Research progress on
resistance mechanisms of epidermal growth factor receptortyrosine
kinase inhibitors in non-small cell lung cancer. Zhongguo Fei Ai Za
Zhi. 15:106–111. 2012.(In Chinese).
|
21
|
Brand TM, Iida M, Li C and Wheeler DL: The
nuclear epidermal growth factor receptor signaling network and its
role in cancer. Discov Med. 12:419–432. 2011.PubMed/NCBI
|